A corporate venture firm of a publicly listed pharmaceutical group has successfully invested and established several IPO companies in Asia. The firm now focuses on strategic investments which can synergize with its portfolio companies or future business. The firm is open to consider investment opportunities globally, and is willing to help overseas portfolio companies enter into Asia through licensing or joint venture activities. Typical allocation size can range from US$3-20 million.
The firm is investing strategically in selected sectors. Within therapeutics, the firm considers in companies with technology platforms in cell therapy, RNA therapies, bispecific and ADC drugs. Investment stage can range from preclinical to early clinical stage. The firm is also interested in investing in early-stage CDMO companies in the areas above.
The firm is looking for experienced management teams with proven track records. The firm typically requests a board seat in its portfolio company.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Corporate VC Firm of Publicly Listed Pharmaceutical Actively Seeks Platform Therapeutics Companies in Promising Modalities, Investing Up to $20M
29 JunHot Investor Mandate: Large PE Firm With US & Asia Offices Invests Up to $20M in Early-Stage Life Science Opportunities, and Up to $50M in Growth-Stage Opportunities
29 JunAn investment firm with offices in USA and Asia is currently making investments from a $1B+ fund in promising private healthcare companies. The firm also has another dedicated fund to invest in promising public healthcare companies, and another fund to invest primarily in early-stage innovations. The firm invests exclusively in the healthcare sector and invests primarily in the USA and Greater China but will also invest in other regions such as Europe and ASEAN countries. Within China, the firm makes growth investments in companies but also find some companies with interesting and innovative early-stage products in recent years there; in the USA and other regions, the firm makes both venture and growth-equity stage investments in both pre-revenue and revenue-stage companies.
The firm’s allocations are highly varied. From the main fund, investments typically range from $20-50m, though larger investments are of interest as well; the early-stage focused fund makes investments of typically $5-20 million. The firm is open to syndication. The firm is also particularly interested in working with companies that are open to or actively interested in seeking partnerships or opportunities in China.
The firm invests in therapeutics, medical devices, diagnostics, healthcare services, and clinically-oriented healthcare IT, and will consider investing in any indication area or technology subsector; however, orphan indications, dermatology/aesthetics, oncology, gene therapy, cell therapy, are of particular interest in the biopharma space; general surgery, neurovascular, cardiovascular, minimally invasive technologies, women’s health, respiratory care, novel diagnostics and orthopedics are of particular interest in the device space. Healthcare AI is an area that the firm is interested and exploring. The early-stage focused fund focuses on early-stage, pre-clinical opportunities in biotech; from the main fund, the firm in most cases makes investments in products that have obtained market approval or are very close to commercialization, but earlier investments may be considered for highly innovative products or products that can demonstrate strong efficacy signals at an earlier stage (such as anti-infectives). For devices and diagnostics, the firm only invests in commercial-stage companies. Generally, the firm does not invest in imaging.
The firm is flexible regarding management teams and works with both serial entrepreneurs and entrepreneurs who lack industry experience. In addition to investing in private companies, the firm is able to invest in public companies by means of PIPEs or public market placements. The firm is interested in investing in companies with products that can demonstrate cost-effectiveness.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Impact Focused VC Seeks to Invest in Therapeutics, Devices, Diagnostics Companies, Typical Check Sizes in $5-10M Range
29 JunA Life Sciences investment firm in the USA is raising an impact-focused fund with an expected first close of $50M USD in late 2023, to target life sciences companies addressing critical health disparities in the US and globally.
The firm leverages venture creation and private equity strategies to create nimble and focused pre-seed to seed-stage companies with aligned interests, providing resources and expertise that allow these companies to develop quickly. This also includes externalizing undervalued assets that meet its thesis in public and late-stage platform companies for rapid development.
The investment size is within the $5M-10M range across an investment cycle, and the firm anticipates deploying 3-5 companies within the next year.
The firm will consider therapeutics, diagnostics, and medical devices that advance health equity. The firm does not consider digital health. Within therapeutics, the firm is modality-agnostic and looks at technologies from Pre-clinical to Phase 2. Within diagnostics and medical devices, the firm is opportunistic and looks at technologies in development and clinical phases. The firm is open to all indications that address the needs of underserved minorities.
The firm adopts a case-by-case approach, so has no preliminary requirements of the management team. The firm prefers to lead its early rounds and require board seating.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Newly Founded VC Fund Invests Up to $8M in Global Therapeutics Companies in All Modalities and Disease Areas
29 JunA venture capital firm with offices in the US and Western Europe is backed by an investment team where everyone has a scientist or medical background. The firm solely invests in therapeutics companies in Seed and Series A rounds. The firm is currently investing from their inaugural global fund – typical check size is up to $8M USD for the first round and may reserve for subsequent rounds. The firm can participate in leading investments or co-investing.
The firm solely invests in specialty therapeutics areas with significant clinical unmet needs. Within therapeutics, the firm is open to all modalities and diseases including orphan diseases. The company needs to be at least 2 years from or in the clinical trial stages.
The firm continues to support the company thus requires taking a board seat, however the firm does not have specific management team requirements.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Exhibit at RESI September
29 JunBy Greg Mannix, Vice President International Business Development, General Manager Europe, LSN
RESI is back to an in-person format with a hybrid digital component, and the feedback from exhibitors at our recent conferences has been amazing. The opportunity to engage potential customers from the 300+ early-stage companies that attend RESI, plus the brand visibility, make RESI ideal for service providers catering to these companies developing technologies in drugs, devices, diagnostics and digital health.
Tomorrow is the last day to benefit from Super Earlybird pricing for the upcoming RESI Boston September 18th conference at the Boston Park Plaza. Reach out to one of our BD team members to reserve your spot or for more information.
Past RESI Sponsors and Exhibitors
| Life Science Nation Business Development Team | |||
| International | East Coast (USA) & China | Midwest (USA) & Canada | West Coast (USA) |
 |  |  |  |
| Greg Mannix Vice President International Business Development Book a Meeting Email Me | Candice He VP, Business Development & Global Investment Strategist Book a Meeting Email Me | Antoinette Lowre Manager of Business Development Book a Meeting Email Me | Cameron Hurlburt Manager of Business Development Book a Meeting Email Me |
FREE Summer Webinar Series for the Early-Stage Entrepreneur
29 JunBy Karen Deyo, Director of Product, Israel BD, LSN
We are excited to announce our summer webinar schedule! This summer, we will be featuring many sessions on diverse topics that can give companies valuable information on how to increase exposure, in the session on Preparing for the Innovator’s Pitch Challenge, and improving their messaging, in the Marketing, Writing Style & Campaign Content session.
LSN’s CEO, Dennis Ford, will be holding a special 3-week webinar series, with one session a week offering valuable insights for first-time entrepreneurs on how to transition from a scientist to a successful entrepreneur with the webinars, First Time CEOs, Launching Your Startup and It All Starts With A Story. Make sure to mark your calendars through the links below and join us for these exciting sessions!
| July 12 11AM ET | Preparing for the Innovator’s Pitch Challenge (IPC) Maximizing your exposure to investors is critical to a successful fundraising campaign, and participating in pitch events plays a large role in that. The RESI Innovator’s Pitch Challenge has been designed to give companies a platform to promote their companies, practice their pitch, and get feedback from a panel of relevant investors and industry experts. Join this session to learn what you can gain from participating in the IPC and how to apply. | SignUp |
| July 25 12PM ET | First Time CEOs This session will cover some of the most common pitfalls that catch first-time and serial entrepreneurs off guard. From false premise and being tentative to surrounding yourself with executives that do not have augmentative and complimentary skillsets, there are many things that can slow the growth of your early-stage life science entity. By learning how to avoid these issues and not run yourself over, your chances of making it to the market will increase greatly. | SignUp |
| Aug. 1 12PM ET | Launching Your Startup Launching a startup begins with commitment. Commitment to your startup initiative, your executive team, and your partners. Learn how to sustain this commitment by creating a proof of concept or prototype and create market traction initially, considerations to your corporate structure, simplifying finances in the beginning and what tools to utilize. This presentation walks you through an honest look at best practices to launch a life science startup. | SignUp |
| Aug. 8 12PM ET | It All Starts with A Story The most successful entrepreneurs are always the best storytellers. Finding a way to naturally formulate your company’s unique story and portraying this through multiple modalities whether it be a 1-minute elevator pitch or a 12-slide pitch deck is one of the most effective ways to get potential investors and partners on board with your value proposition. This bootcamp will cover the importance of entrepreneurial agency, finding your voice and developing a compelling narrative for the different players that will emerge along a deal chain, and language tools to refine your hook. | SignUp |
| Aug.16 12PM ET | Tech Hub Exposure at RESI This webinar is designed for tech hub organizations ranging from accelerators, incubators, non-profits, universities, tech transfer offices, regional organizations, and more who set up their early-stage life science startup constituents for success with their entrepreneurship and fundraising journey. It will showcase the tools and resources that LSN makes available for Tech Hubs to help their startups who’ve raised less than $2M USD in capital expand their outreach from Regional to Global, build a target list of investors, get involved with the RESI conference series, and more. | SignUp |
| Aug. 22 12PM ET | Partnering Tutorial Understanding the RESI partnering system and using it to its maximum capabilities can make a large difference in a company’s success at RESI. Join LSN staff as we walk you through our system and how it can help you identify partners who are a best fit for you, how to manage your outreach, our recommended strategy for following up, and how to take advantage of all of the content that we provide to ensure your best possible RESI experience. | SignUp |
| Aug. 31 11AM ET | Marketing, Writing Style & Campaign Content Marketing is about more than the content – it’s about how you write, and how it speaks to your target audience. One of the biggest pieces of advice we can give companies is to know your audience. This session covers how to tailor your language to the different players you will speak to within investor and partner firms, and how to spread your message effectively to your target audience. | SignUp |
| Sept. 6 12PM ET | Partnering Tutorial Understanding the RESI partnering system and using it to its maximum capabilities can make a large difference in a company’s success at RESI. Join LSN staff as we walk you through our system and how it can help you identify partners who are a best fit for you, how to manage your outreach, our recommended strategy for following up, and how to take advantage of all of the content that we provide to ensure your best possible RESI experience. | SignUp |
RESI Boston September Panels
29 JunBy Love Chung, Investor Research Analyst, LSN
RESI Boston September will take place in person at the Boston Park Plaza on September 18th, followed by 2 days of virtual partnering on September 19th – 20th. Included will be seven investor panels that provide experts’ insights on trending topics in the life sciences.
We will be introducing two new investor panels at RESI Boston September: Synthetic Biology and Strategic Partners. The successful Women’s Health panel will also be brought back from the recent RESI Boston June. Make sure to register by TOMORROW, Friday, June 30 for Super Early Bird tickets to save $500! Check out the panel topics below:
| RESI Boston September Investor Panels | |
| 9AM ET | Oncology Innovation Panel |
| 10AM ET | Women’s Health Panel |
| 11AM ET | Synthetic Biology Panel |
| 1PM ET | Diagnostics Investor Panel |
| 2PM ET | Strategic Partners Panel |
| 3PM ET | Family Offices Panel |
| 4PM ET | AI in Healthcare Panel |
Subscribe
Life Science Nation
RESI Conference Series
Investor Platform Demo
Company Platform Demo
Next Phase Newsletter 